Phencyclidine (PCP): Neurobiology, Clinical Effects, Acute Toxicity, and Evidence-Based Management of Intoxication

Phencyclidine (PCP), also known as “angel dust,” is a dissociative anesthetic that produces profound alterations in perception, behavior, and consciousness. Clinically, PCP intoxication is characterized by a spectrum ranging from mild agitation and ataxia to severe respiratory compromise, hyperthermia, seizures, and rhabdomyolysis. Understanding PCP’s neuropharmacology is central to accurate risk assessment and timely, evidence-informed management.

Mechanism of action: PCP primarily acts as a noncompetitive antagonist at N-methyl-D-aspartate (NMDA) receptors. By blocking NMDA-mediated glutamatergic neurotransmission, PCP disrupts cortical-subcortical network connectivity, contributing to dissociation, analgesia, and cognitive impairment. NMDA inhibition also secondarily alters dopaminergic, serotonergic, and noradrenergic signaling, which can manifest as agitation, hallucinations, and dysregulated motor activity. These receptor-level effects help explain why PCP intoxication may present with both psychotomimetic features and profound motor incoordination.

Clinical presentation: Patients may present with nystagmus, slurred speech, unsteady gait, generalized hyperreflexia, and muscle rigidity. Behavioral effects include agitation, paranoia, and unpredictable aggression, sometimes with apparent analgesia despite painful injuries. Vital sign abnormalities can include hypertension, tachycardia, tachypnea, and variable temperature elevation. Severe toxicity can progress to seizures, coma, respiratory depression, and metabolic derangements such as acidosis. A high-risk complication is rhabdomyolysis, driven by muscle overactivity, hyperthermia, and direct physiologic stress; this can lead to acute kidney injury if untreated.

Psychiatric and neurologic sequelae: Acute intoxication may mimic primary psychotic disorders, with hallucinations and delusional thinking. Because PCP can impair reality testing and executive function, diagnostic confusion is common in emergency settings. Recovery can be prolonged, particularly after severe episodes; residual cognitive deficits, mood symptoms, and sleep disruption have been reported. While “flashbacks” are classically associated with hallucinogens like LSD, dissociative agents may also produce perceptual disturbances beyond the acute phase, warranting careful follow-up.

Risk factors: Severity increases with dose, polysubstance use (especially with opioids, stimulants, or alcohol), delayed presentation, and underlying medical vulnerabilities such as liver or kidney disease. Co-ingestion may obscure the primary toxidrome and increase the likelihood of complications (e.g., aspiration, hypoxia, arrhythmias). The unpredictable behavioral effects also raise risks of trauma, falls, and self-harm.

Assessment and differential diagnosis: A structured approach is essential. Clinicians typically evaluate airway, breathing, and circulation first, then obtain glucose to exclude hypoglycemia. Neurologic assessment includes checking for seizure activity, rigidity, focal deficits, and signs of head trauma. Labs often include electrolytes, renal function, creatine kinase (CK) for rhabdomyolysis, arterial blood gas or venous blood gas for acid-base status, and lactate when shock or severe agitation is suspected. Urinalysis and toxicology screening can support identification, though availability and sensitivity vary; management should not be delayed for confirmatory tests. Differential diagnosis includes intoxication with other dissociatives (e.g., ketamine), stimulants, anticholinergics, and neurologic emergencies such as stroke or meningitis.

Evidence-based acute management: The cornerstone is supportive care. If the patient is agitated or at risk of harm, a calm environment and verbal de-escalation are first-line. Benzodiazepines are commonly used for sedation, controlling agitation, and treating seizures; dosing is titrated to clinical response and respiratory status. Airway protection is critical in patients with declining consciousness or hypoventilation. For hyperthermia, aggressive cooling and monitoring of temperature are indicated. Management of rhabdomyolysis includes early IV isotonic fluids to maintain renal perfusion and mitigate myoglobin-induced nephrotoxicity; CK and urine output guide ongoing therapy.

Long-term care and prevention: After stabilization, patients benefit from screening for substance use disorder, mental health comorbidities, and trauma exposure. Motivational interviewing and referral to addiction services can reduce recurrence. Because PCP can produce transient psychotic-like symptoms, clinicians should reassess for persistent hallucinations or mood disturbances after acute clearance; if symptoms persist, further psychiatric evaluation is warranted. Harm-reduction counseling should address polysubstance risks, safer use practices where applicable, and early emergency evaluation for confusion, seizures, or high fever.

Prognosis: Outcomes depend on exposure severity, timeliness of supportive interventions, and co-ingestants. With prompt airway support, seizure control, temperature management, and hydration for rhabdomyolysis, many patients recover. However, severe complications—especially aspiration, severe rhabdomyolysis with renal failure, or prolonged hypoxia—can result in lasting morbidity.

Source: @dariusimperator